In glioma, mutant IDH1 is deficient in performing its oxidative reaction by >80% [383] with an approximate 38% reduction in NADPH generation [384], thus highlighting the metabolic consequences of mutation on its enzymatic and metabolic function. Here, IDH1 is linked to central nervous system cancer.